



MAYNE PHARMA RECEIVES \$14.4M PAYMENT FOR LEGAL COSTS FROM COSETTE

5 June 2026, Adelaide, Australia: Mayne Pharma Group Limited (Mayne Pharma or the Company) (ASX: MYX) refers to its announcement on 22 May 2026.

Mayne Pharma confirms that it has today received a total of \$14,410,714.49 from Cosette Pharmaceuticals, Inc (**Cosette**), paid in accordance with orders made by the Supreme Court of New South Wales (**Court**) on Friday, 29 May 2026. This amount comprises recovery of Mayne Pharma's legal costs, costs associated with Mayne Pharma's application for costs, and interest.

This is another successful milestone in the proceedings commenced by Mayne Pharma against Cosette in June 2025 in relation to Cosette's purported termination of the Scheme Implementation Deed signed by Mayne Pharma and Cosette in February 2025. In October 2025, the Court delivered judgment in favour of Mayne Pharma dismissing all of Cosette's claims. The Court also made an adverse costs order against Cosette, requiring Cosette to pay Mayne Pharma's costs of the proceedings as agreed or assessed.

Mayne Pharma notes that in January 2026, Cosette appealed the Court's October 2025 judgment. The appeal was heard in the Supreme Court of New South Wales, Court of Appeal on 2 and 3 June 2026 and a decision has been reserved.

- ENDS -

For further information contact:

Dr Tom Duthy
Investor Relations
+61 402 493 727
ir@maynepharma.com

Authorised for release to the ASX by the Board Chair.

Email Alerts

To register for an email alert service to receive Mayne Pharma announcements released to the Australian Securities Exchange (ASX) please visit <https://www.maynepharma.com/investor-relations/email-alerts/>

Follow us on [LinkedIn](#)

Mayne Pharma Group Limited

ABN 76 115 832 963

[maynepharma.com](https://www.maynepharma.com)

1538 Main North Road, Salisbury South, SA 5106 Australia



ASX Announcement

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma is a leader in dermatology and women's health in the United States and also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit maynepharma.com.